Exciting news today as Biosense Webster receives European CE mark approval for our VARIPULSE™ Platform, marking a significant step forward in treating cardiac arrhythmia with pulsed field ablation (PFA) technology. With estimates suggesting that by 2050, Europe will have the greatest increase in Atrial Fibrillation compared to other regions globally, this milestone not only signifies our commitment to innovation in cardiac care but also positions us here in Europe at the forefront of solving some of the most pressing challenges in cardiac care. Our focus now is working alongside physicians and healthcare providers, together with our leading clinical teams throughout the region to bring this technology to all those patients who can benefit. https://lnkd.in/edYARrJz #myCompany #CardiacCare #JNJMedTechProud #VARIPULSE #PulsedFieldAblation
Congratulations!!! Very exciting.
Congratulations!!
Director of Electrophysiology Service @ AHVC
5moGreat to see more development in single shot PFA. Congrats